Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422915 · ClinicalTrials.gov registry record · Phase 2
Sorbent Therapy of the Cutaneous Porphyrias
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01422915: Completed Phase 2 study, sponsored by Brigham and Women's Hospital.
NCT01422915 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01422915, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).
Primary Outcome
Minutes of sun tolerance
Interventions
- DRUG Colestipol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
What the finished NCT01422915 record still lists
NCT01422915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Colestipol is the first listed.
NCT01422915 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01422915 about?
NCT01422915 is a clinical study titled "Sorbent Therapy of the Cutaneous Porphyrias". The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered coles...
What is the current status of trial NCT01422915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2011-05. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01422915?
The interventions under investigation include: Colestipol (DRUG).
Who is sponsoring clinical trial NCT01422915?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01422915's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia